Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ray Woosley, Jean-Francois Formela, Amelia Wall Warner, Ted Snelgrove


ARCA Biopharma, a firm developing genetically targeted treatments for cardiovascular diseases, has appointed Ray Woosley to its board of directors. Woosley, president emeritus of the Critical Path Institute, will serve on the compensation , nominating, and corporate governance committees of ARCA's board of directors.

From 2005 to 2011, Woosley served as the president, CEO, and chairman of the C-Path Institute, a non-profit, public-private institute with the US Food and Drug Administration that he founded. Last year, Woosley became president and board chairman of the Arizona Center for Education and Research on Therapeutics, an independent, nonprofit organization focused on medication safety research and education.

ARCA also announced that Jean-Francois Formela, a partner at Atlas Ventures, has resigned from its board of directors after being a member since 2006.

Amelia Wall Warner is the new president of Gentris Corporation. Warner will oversee the company's US operations, be responsible for the development of new service offerings, and advance biobanking and pharmacogenomics training programs.

Warner comes to Gentris from Merck Research Laboratories, where she was head of clinical pharmacogenomics and clinical specimen management. Warner is also CEO and founder of Global Specimen Solutions and a past chair of the Industry Pharmacogenomics Working Group.

The prenatal genetic testing company Cellscape said that Ted Snelgrove has become its new CEO. Snelgrove previously was VP of sales and marketing for Genomic Health, where he led the commercial development and launch of the Oncotype Dx test. He most recently was chief commercial officer for Crescendo Bioscience, and he has worked in business development, marketing, and product management at Amgen, ALZA, Immunex, and Eli Lilly.